Uni-Bio Science Group
20 Science Park East Avenue, Sha Tin, New Territories, Hong Kong
Overview
Uni-Bio Science Group (HKEX: 0690) is a Chinese biopharmaceutical company engaged in the research, development, production and commercialisation of biopharmaceuticals for the Chinese healthcare market.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 0
Sector focus
- Biopharma
- Biotechnology
Investment portfolio
- Spiral Therapeutics
Participated · Series B · Apr 2026
Spiral Therapeutics is a clinical-stage biotech company focused on developing therapies for inner ear disorders, including hearing loss and balance disorders, and advancing its MICS™ (Minimally-Invasive Cochlear System) drug delivery platform. The company’s lead program, SPT-2101, produced a statistically significant reduction in overall vertigo in patients with Ménière’s disease, and Spiral is preparing for a registrational clinical trial. Spiral’s pipeline also includes neurotrophic approaches and other hearing loss programs enabled by precision cochlear delivery. Recent financing will fund continued development of SPT-2101 and expansion of the MICS™ platform. Spiral announced an R&D collaboration with Advanced Bionics to evaluate sustained local drug delivery at the time of cochlear implantation. The company is based in South San Francisco.
Team
No current team members are available.